Ketoconazole Hasco

Ketoconazole, the active ingredient in Ketoconazole Hasco, is an azole antifungal presented as an oral formulation for systemic use. It is indicated for systemic candidiasis, dermatophytosis, seborrheic dermatitis (off‑label) and other susceptible fungal infections in adult patients.

GNH USA supplies Ketoconazole Hasco as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with distribution rooted in the European Union market. All batches meet EU GMP standards and are shipped under controlled conditions, ensuring product integrity throughout the supply chain.

Ketoconazole is an azole antifungal that interferes with fungal cell membrane synthesis.

- Systemic candidiasis: effective in eradicating bloodstream and deep‑tissue Candida infections. - Dermatophytosis: helps clear skin infections caused by dermatophyte fungi. - Seborrheic dermatitis (off‑label): reduces inflammation and scaling associated with the condition.

Ketoconazole may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: discomfort or cramps in the abdomen. - Headache: transient head pain. - Rash: skin redness or itching. - Taste alteration: metallic or altered taste perception. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, potentially fatal. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - QT interval prolongation: risk of cardiac arrhythmias. - Adrenal insufficiency: suppression of cortisol production. - Anaphylaxis: life‑threatening allergic response.

Before prescribing ketoconazole, clinicians should consider several safety measures.

- Assess liver function: obtain baseline hepatic enzyme tests. - Monitor hepatic enzymes: repeat testing periodically during therapy. - Avoid in known azole hypersensitivity: discontinue if allergic reaction occurs. - Use caution with cardiac arrhythmias: evaluate QT interval risk. - Avoid concomitant strong CYP3A4 inhibitors: may increase ketoconazole levels. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Ketoconazole interacts with several medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may cause toxic accumulation. - QT‑prolonging agents (e.g., cisapride): increase risk of serious arrhythmias. - Hepatotoxic drugs (e.g., isoniazid): may exacerbate liver injury.

Moderate Interactions (Monitor Closely): - CYP3A4‑metabolized statins (e.g., simvastatin): risk of increased statin exposure. - Warfarin: potential alteration of anticoagulant effect. - Oral contraceptives: possible reduction in hormonal efficacy.